Bluejay Diagnostics (NASDAQ:BJDX) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Bluejay Diagnostics (NASDAQ:BJDX) to a sell rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Bluejay Diagnostics currently has a consensus rating of “Sell”.

Bluejay Diagnostics Price Performance

Shares of Bluejay Diagnostics stock opened at $1.45 on Friday. The company has a market capitalization of $1.49 million, a price-to-earnings ratio of -0.12 and a beta of 0.88. The business has a fifty day simple moving average of $2.64 and a two-hundred day simple moving average of $2.44. Bluejay Diagnostics has a 1 year low of $1.03 and a 1 year high of $16.68.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.95) earnings per share (EPS) for the quarter.

Insider Buying and Selling at Bluejay Diagnostics

In other news, major shareholder Financial Lp Hrt sold 34,938 shares of Bluejay Diagnostics stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $1.40, for a total transaction of $48,913.20. Following the completion of the sale, the insider owned 92,055 shares in the company, valued at approximately $128,877. This trade represents a 27.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 6.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new stake in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics as of its most recent filing with the SEC. 18.47% of the stock is owned by institutional investors.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.